Kornimate/medical-research-clean huggingface dataset:
written document to assist family during decision of withholding and withdrawing life-sustaining therapies in the intensive care unit

Conditions: Post Traumatic Stress Disorder

Summary: relatives of patients in situation of withholding and withdrawing life-sustaining therapies often show post traumatic stress disorder (ptsd) (60%)\[1\]. this number is even greater when family members are active in this decision (81%) or when communication is not optimal between medical team and family members. there are several ways to assist families of patients in intensive care units \[2\], amongst them the use of a written document to explain the environment, therapies and possible outcomes. here the investigators want to test the impact of a written document in the context of end-of-life conference in intensive care units. specifically, this research addresses wether such written support could decrease 3-months post-traumatic stress disorder, anxiety and depression exhibited by the closest family member or the patient representative.


Eligibility criteria:
the study will enroll patient representant (family member or close friends designed by the family or pre-admission legal representant). inclusion criteria: * medical team anticipates a decision to withhold and withdraw life-sustaining therapies to intensive care unit (icu) discharge * verbal consent to participate * able to communicate in french exclusion criteria: * representant of a patient \< 18 years old * representant of a patient whose stay in icu lasted less than 48 hours * representant of a patient without social security
recurrent esbl-producing enterobacteriaceae bacteremia: risk factor, molecular character and susceptibility change

Conditions: Bacteremia

Summary: the purpose of this study is to investigate the risk factor, molecular character and susceptibility change for recurrent esbl-producing enterobacteriaceae bacteremia

1. to characterize the genotypes of the pathogens isolated from recurrent esbl-ek bacteremia versus non-recurrent esbl-ek bacteremia to differentiate relapse from reinfection * recurrent versus non-recurrent * relapse versus reinfection 2. to correlate the patient characteristics, clinical manifestations, severity of illness (the modified pitt bacteremia score), diagnosis of deep-site infection, co-morbid conditions (including diabetes mellitus, hepatic and renal dysfunction), length of stay in icu/hospitalization, the presence of invasive procedures, source of pathogen (community acquired or nosocomial infection), antimicrobial regimen (i.e carbapenems versus non-carbapenems(flomoxef or quinolones), microbiological characteristics (e coli and kleb. pneumoniae) and outcome endpoints (clinical outcome and mortality) with esbl recurrence and genotypes

Eligibility criteria:
inclusion criteria: * adult patients (age\>=18 years) with at least one episode of esbl-ek bloodstream infection from august 2004 to july 2010 exclusion criteria: * patients who died within 48h after first episode of esbl-ek bloodstream infection
effectivity of allogenic umbilical cord mesenchymal stem cells conditioned media for osteoarthritis of the knee joint

Conditions: Osteoarthritis Knee

Summary: osteoarthritis (oa) is a joint disorder that often occurs and causes disability. this disorder is characterized by an inflammatory reaction in the synovial joints accompanied by a gradual degeneration process in the articular cartilage and sub-chondral bone. current research has discovered that stem cells produce conditioned media (secretome, extra vesicles, and exosomes) that have tissue regeneration, immunomodulation, anti-inflammatory, and anti-apoptotic capabilities. research on conditioned media for umbilical cord mesenchymal stem cells is still at the in vivo stage in experimental animals. for this reason, this study aims to conduct clinical experimental research (translational study) in patients with knee joint oa who were given umbilical cord mesenchymal stem cell conditioned media via intra-articular injection.

the research was conducted as a clinical trial and translational study, involving a single group treated with intra-articular secretome injection therapy derived from hypoxic umbilical cord mesenchymal stem cell conditioned media. this study explores the clinical application of conditioned media from umbilical cord mesenchymal stem cells for treating knee oa. our preliminary clinical trial involves administering this conditioned media via intra-articular injections to patients, followed by assessments using functional scores and mri with t2 mapping sequence. this approach aims to harness the therapeutic potential of msc derivatives in a clinical setting, offering a novel and potentially less invasive alternative to conventional oa treatments. the aim of this study is to evaluate the effectiveness of intra-articular injections of conditioned media from umbilical cord mesenchymal stem cells in improving knee joint function and structural integrity in patients with osteoarthritis, as assessed by mri and functional scoring.

Eligibility criteria:
inclusion criteria: * age over 45 years * primary knee joint oa kellgrance-lawrence grade 2 or 3, * never had surgery or intra-articular injection before, exclusion criteria: * currently experiencing local infections and/or systemic infections, * have a history of autoimmune disorders or immunodeficiency, * have had surgery or injections on the knee joint,

Keywords: osteoarthritis knee mesenchymal stem cell conditioned media
biomarkers in tissue samples from patients with ewing sarcoma

Conditions: Sarcoma

Summary: rationale: studying samples of tissue in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors understand how well patients respond to treatment. purpose: this research study is studying biomarkers in tissue samples from patients with ewing sarcoma.

objectives: * to describe the spectrum of ggaa-microsatellite polymorphisms at specific loci in genomic dna prepared from ewing sarcoma tumor specimens. * to determine if there are differences in ggaa-microsatellite polymorphisms in genomic dna prepared from ewing sarcoma tumor specimens as compared to non-afflicted european and african normal genomic dna. * to determine if ggaa-microsatellite polymorphisms at specific loci in genomic dna prepared from ewing's sarcoma tumor specimens correlates with disease outcome in patients treated on cog protocol aews0031. * to determine whether whole-genome amplification introduces alterations in ggaa-microsatellites as compared to non-amplified genomic dna. outline: genomic pcr is used to amplify the microsatellites in the nr0b1 and gstm4 promoters. in addition to determining microsatellite size, each microsatellite is sequenced following cloning into the pcr4 vector (invitrogen) using standard topoisomerase cloning protocols.

Eligibility criteria:
disease characteristics: * specimens from patients with ewing sarcoma used for protocol cog-aews08b1 * obtained from patient samples taken from patients enrolled on cog-aews0031 * whole genome-amplified dna will be used patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: localized ewing sarcoma/peripheral primitive neuroectodermal tumor
l-prf in alveolar ridge preservation

Conditions: Bone Loss, Alveolar

Summary: the effect of leucocyte- and platelet-rich fibrin (l-prf) for enhancing the healing after dental extractions is still a matter of debate. the available literature suggests that l-prf performs positive effect to improve alveolar preservation resulting in less bone resorption on extraction sockets. l-prf is a second generation of platelet concentrate produced without biochemical blood manipulation. l-prf is composed by three key parameters: first, the presence of platelets; second, the presence of leucocytes; third, the density and complex organization of the fibrin matrix architecture produced by a natural polymerization process. the theory is that this key parameters acts to produce a faster bone healing.


Eligibility criteria:
inclusion criteria: * (1) health patients, american society of anesthesiologists (asa) i or ii * (2) patients who need to submit tooth extraction (pre-molar, canine and incisor teeth - uniradicular teeth or teeth with fused roots) which present ideal conditions to receive dental implants after 3 months. exclusion criteria: * smoking * systemic diseases related with healing disorders * poor oral hygiene * pregnant or lactating patient * use of flap elevation for dental extraction

Keywords: platelet-rich fibrin tooth extraction alveolar bone grafting
antegrade arterial and portal flushing versus portal flushing only in ldlt

Conditions: Biliary Complications; Graft Function, Delayed

Summary: arterial flushing is a standard recommendation in deceased donor liver transplantation but not in living donor liver transplantation due to the risk of arterial intimal injury and short cold ischaemia time. there is recent evidence on benefit of retrograde arterial perfusion using hepatic venous occlusion and its benefits on post transplant cholestasis. however there is no data on antegrade arterial flushing.

biliary reconstruction has been labeled the "achilles heel" of liver transplantation and is a common cause of postoperative morbidity and also mortality .living donor liver transplantation (ldlt) has a higher incidence of biliary complications of up to 30% which is higher than deceased donor liver transplantation and does not seem to improve significantly with experience.the virtually unchanged incidence of biliary strictures suggests that they are not simply "technical" in origin, but probably represent a mucosa ischemic injury inherent in the transplantation procedure. the blood supply of the bile duct is mainly from the arterial system and skeletonisation of the duct during dissection impairs the blood supply rendering it ischemic. various donor maneuvers for better flushing and preserving peribiliary vascular plexus and biliary mucosa have been studied to decrease biliary complications. ldlt have advantages of haemodynamic stable donor and short cold ischemia but also has disadvantages of small graft size, small ducts, complicated reconstruction and absence of arterial flush. conventional portal flush in animal livers could not remove warm blood from the arterial system and grafts without retrograde arterial flush had higher post operative bilirubin.with further studies in living donor liver transplant, it was concluded that retrograde flushing may ameliorate post operative cholestasis. there has not been data published on antegrade arterial flushing and its effect on biliary complications in living donor liver transplant. this study aims to compare back table graft arterial and portal flushing with portal flushing alone and evaluate biliary and arterial complications. arterial flushing has been made part of standard protocol at our institute and its safety established. there are centers which routinely perform back table arterial flush.

Eligibility criteria:
inclusion criteria: * all patients undergoing living donor liver transplant for decompensated chronic liver disease with right lobe grafts only exclusion criteria: * donor artery size less than 2 mm * more than one donor artery * grwr \<0.8 * abo incompatible grafts * refusal to participate in the study * emergency transplants
is local injection of mesenchymal stem cells after endoscopic dilation safe and does it improve the outcome of intestinal stricture in patients with crohn's disease?

Conditions: Safety Issues; Efficacy

Summary: this is an exploratory phase ii study, to evaluate the impact of these mesenchymal stem cells (mscs) on strictures in crohn's disease patients with symptomatic intestinal stricture eligible to endoscopic dilatation. the impact of combined treatment by endoscopic dilation and local injection of mscs will be compared with that of a control group.


Eligibility criteria:
inclusion criteria: * patient aged ≥ 18 years with crohn's disease diagnosed more than 6 months ago * background treatment, for crohn's disease, stable for 4 months * presence of stricture (whether de novo or anastomotic), meeting the radiological definition of stenosis, i.e. a combination of the following criteria: (1) localized luminal narrowing (reduction of luminal diameter by at least less than 50% compared to adjacent healthy bowel segment), (2) bowel wall thickening (25% increase in wall thickness compared to adjacent unaffected bowel) and pre-stenotic dilation (luminal diameter greater than 3 cm) * presence of symptomatic stricture with abdominal pain after meals and limitations on the amount or type of food at screening * presence of a stenosis accessible by ileo-colonoscopy, not passable (i.e. not allowing the passage of the adult ileo-colonoscope), of a length less than 5 cm, eligible for endoscopic dilation * patient accepting the study protocol and having signed an informed consent * patient capable of undergoing entero-mri exclusion criteria: * patient liable for immediate surgery * patient with intra-abdominal fistula or abscess * patient with a stenosis not accessible to ileocolonoscopy * patient presenting ≥ 2 strictures with impossibility of determining which stenosis is "dominant" and responsible for the symptoms (based on dilation in entero-mri) * patient with a stenosis longer than 5 cm * patient with a contraindication to performing an entero-mri or to the use of contrast product injection in entero-mri (gadolinium) * pregnant woman or planning a pregnancy in the year * patient with kidney insufficiency (with anuria, glomerular filtration rate \ 3 mg/dl) * patient with documented human immunodeficiency virus (hiv) infection, active hepatitis b or c or tuberculosis * patient having presented an opportunistic infection in the 6 months preceding inclusion or a serious infection in the previous 3 months * patient who has developed a malignant tumor with a history of lymphoproliferative disease with the exception of: non-melanoma skin cancer, carcinoma in situ (e.g. skin, cervix, bladder, breast) and in remission for at least 3 years prior to screening, superficial bladder cancer, asymptomatic low-grade or localized curatively treated prostate cancer for which the "watch-and-wait" approach is the standard of care as well as any other cancer that has been in remission for ≥ 3 years prior to enrollment.
transport of artificial sweeteners during pregnancy

Conditions: Pregnancy Related; Diabetes; IUGR

Summary: with obesity on the rise worldwide more and more young women are also affected, leading to a higher prevalence of obese pregnant women and pregnant women with diabetes. children of these women are in risk of developing obesity during childhood which again leads to overweight during adult life resulting in life-style related diseases such as diabetes and cardio-vascular disease. overweight and diabetic women are currently advised to substitute sugar sweetened beverages with artificially sweetened beverages to lower caloric intake and avoid fluctuations in blood glucose to avoid complications during pregnancy for both mother and child. recent studies suggest that high intake of artificial sweeteners during pregnancy increases the risk of the child developing obesity. if this is indeed true, the current guidelines have the opposite of the wanted and children already in risk of overweight are exposed to extra risk. to investigate if artificial sweeteners can affect the foetus, the investigators wish to examine whether artificial sweeteners can cross the placenta. the study is a clinical trial in which 40 women will be enrolled. 30 participants will drink a diet soft drink 2 hours before a caesarean section and 10 controls will refrain from intake. after birth the investigators will obtain a blood sample from the mother and from the umbilical cord and a placental biopsy and measure the contents of artificial sweeteners. furthermore, the investigators will obtain a sample of amniotic fluid to examine if the sweeteners are excreted into the amniotic fluid. the results ultimately have the potential to change the current guidelines on diet for overweight and diabetic women during pregnancy.


Eligibility criteria:
inclusion criteria: * elective caesarean section * child with iugr (10 subjects) * diabetes (10 subjects) * other reasons for caesarean section(10 healthy subjects in intervention + 10 healthy controls) exclusion criteria: * acute caesarean section

Keywords: artificial sweeteners non-nutritive sweeteners caesarean section
trial of linaclotide administered to patients with irritable bowel syndrome with constipation

Conditions: Irritable Bowel Syndrome Characterized by Constipation

Summary: the objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (ibs-c). the primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for abdominal pain and complete spontaneous bowel movement (apc) responder.


Eligibility criteria:
inclusion criteria: * patient meets protocol criteria for ibs: reports abdominal discomfort or pain that has two or more of the following three features: 1. relieved with defecation 2. onset associated with a change in frequency of stool 3. onset associated with a change in form (appearance) of stool * patient reports \ 25% of bms * patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ecg, or clinical laboratory tests (some patients may require a colonoscopy per american gastroenterological association (aga) guidelines) * patient is compliant with interactive voice response system (ivrs) for daily diary reporting of bm habits and ibs symptoms exclusion criteria: * patient has history of loose or watery stools for \>25% of bms * patient has a structural abnormality of the gastrointestinal (gi) tract or a history of a disease or condition that can affect gi motility * patient has any protocol-excluded or clinically significant medical or surgical history or concomitant medication use that could confound the study assessments

Keywords: irritable bowel syndrome constipation linaclotide
role of ipsilateral motor cortex in executing movements with increasing demand on precision

Conditions: Stroke

Summary: it is well known that the motor area of one hemisphere of the brain (motor cortex) controls the movement of the opposite of the body. however, it is not clear whether as the movement becomes more complicated, the motor cortex of both hemispheres of the brain are involved. currently the role of the motor cortex on the same side of the body (referred to as ipsilateral motor cortex) in hand performance remains controversial. the investigators demonstrated previously in healthy subjects that transiently lowering the activity of ipsilateral motor cortex improved the performance of the opposite hand. what is not know are the mechanisms involved in these changes of behavior. transcranial magnetic stimulation (tms) is a device that allows the non- invasive stimulation of the brain. when brain is stimulated repetitively at a very low rate and low intensity for about 15 minutes, the stimulated brain area becomes less active. this effect lasts 10 minutes and is called a "transient artificial lesion" as it mimicks the effects of transiently interfering with the function of the stimulated brain area. in the present study the investigators will conduct experiments using repetitive tms to downregulate the activity of the motor area as in previous experiments and measures its effect on activity of motor cortex of both hemispheres. the investigators will study healthy subjects. it would be important to understand the effects in more detail for the design of treatment strategies in patients after stroke, which will be a topic of future studies.


Eligibility criteria:
inclusion criteria for stroke patients: * age 18-80 * single cerebral ischemic infarction one month prior to entering study * affecting only one hemisphere as defined by mri of the brain * at the time of cerebral infarct a motor deficit of hand of medical research council scale for muscle strength (mrc) of \< 4- of wrist and finger extension/flexion movement * fugl meyer score \> 27/66 (motor domain, upper extremity) * ability to operate joystick at largest target level * no other neurological disorder * no intake of central nervous system (cns) active drugs * ability to give informed consent * ability to meet criteria of inclusion experiment * no major cognitive impairment inclusion criteria for healthy subjects: * age 55-80 years with no neurological or psychiatric diseases * normal neurological examination * normal mri of the brain * normal neuropsychological testing * no intake of cns active drugs that interfere with data collection * no contraindication to tms * ability to give informed consent

Keywords: stroke physical medicine & rehabilitation neurology neurophysiology neuroscience transcranial magnetic stimulation (tms)
clinical evaluation of genetron d842v pcr kit in gist patients

Conditions: GIST; Gastrointestinal Stromal Tumors

Summary: the purpose of this trail is to evaluate the performance of genetron d842v pcr kit in gist patients using real-time pcr method.

this trial follows the principle of synchronous blinding. the enrolled cases are coded, and the enrolled samples are detected with genetron d842v pcr kit and sanger sequencing method. the results were determined independently according to the cutoff values or interpretation requirements provided by each method. the safety and effectiveness of this kit are confirmed and evaluated.

Eligibility criteria:
inclusion criteria: 1. paraffin-embedded tissue samples from patients clinically diagnosed with gastrointestinal stromal tumor (gist), and a small number of other cancers or benign lesions in the gastrointestinal site were included as interference samples. 2. the sample should have corresponding basic clinical information, including: the patient's unique traceability number, age, gender, pathological diagnosis results, etc. 3. the sample is a formalin-fixed paraffin-embedded gastrointestinal stromal tumor tissue sample, and each sample can provide 5 paraffin sections or 5 paraffin rolls with a thickness of at least 5 µm. 4. the content of tumor cells meets the requirements of assessment reagents and comparison methods. exclusion criteria: 1. the investigator considers that it is not appropriate to continue the clinical trial, such as the samples that are not prepared according to the required steps. 2. samples that cannot complete the entire testing process. 3. patients with incomplete sample information.